For several tumours, neoantigen load is correlated with survival and with response to immune checkpoint blockade; melanoma and lung adenocarcinoma have higher mutational load, greater T cell infiltration, greater PD‐1 expression and consequently show better responses to anti‐PD‐1 therapy 9. The gene discussed is PDCD1; the disease is melanoma.